Parissis John T, Panou Fotios, Farmakis Dimitrios, Adamopoulos Stamatis, Filippatos Gerasimos, Paraskevaidis Ioannis, Venetsanou Koula, Lekakis John, Kremastinos Dimitrios Th
Second Department of Cardiology and Heart Failure Clinic, Attikon University Hospital, Athens, Greece.
Am J Cardiol. 2005 Aug 1;96(3):423-6. doi: 10.1016/j.amjcard.2005.03.092.
In this randomized, placebo-controlled study, it was found that a 24-hour levosimendan infusion improves echocardiographic markers of abnormal left ventricular diastolic function (transmitral flow patterns and mitral annulus velocities, as assessed by transthoracic pulse-wave Doppler and tissue Doppler imaging, respectively) and reduces substances of excessive neurohormonal activation (plasma B-type natriuretic peptide and interleukin-6) in patients with advanced heart failure. Moreover, levosimendan-treated patients had fewer events and longer progression-free survival during a 5-month follow-up compared with those who received placebo. Thus, levosimendan seems to be effective in improving left ventricular diastolic function and reducing neurohormonal activation in patients with severe heart failure.
在这项随机、安慰剂对照研究中，发现对晚期心力衰竭患者进行24小时的左西孟旦输注可改善左心室舒张功能异常的超声心动图指标（分别通过经胸脉冲波多普勒和组织多普勒成像评估的二尖瓣血流模式和二尖瓣环速度），并减少神经激素过度激活的物质（血浆B型利钠肽和白细胞介素-6）。此外，与接受安慰剂的患者相比，左西孟旦治疗的患者在5个月的随访期间发生的事件更少，无进展生存期更长。因此，左西孟旦似乎对改善重度心力衰竭患者的左心室舒张功能和减少神经激素激活有效。
Zotero 插件